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phasizing which clinical trials need to be conducted within the next 3 
years to reduce NSCLC-related morbidity/mortality, would be of value.
Methods: The SLC in Lung Cancer, an initiative of the CCCG to 
establish and advance national clinical research priorities in lung can-
cer, is a multidisciplinary group with representation from cooperative 
groups, Specialized Programs of Research Excellence, cancer centers, 
and leading academic and community institutions. The initial meeting 
of the SLC in Lung Cancer was held in Philadelphia, Pennsylvania, 
on November 13-14, 2005, followed by a scientiﬁc dialogue with as-
sociated constituencies (patient advocacy groups and pharmaceutical 
companies engaged in lung cancer drug development) in Santa Monica, 
California on January 25-26, 2006. This report summarizes the primary 
research priorities identiﬁed during this series of meetings.
Results: Eight primary research priorities were identiﬁed:
Clinical trial design/accrual
• Identify and address barriers to accrual into adjuvant trials, building 
awareness among patients and clinicians
• Evaluate new measures of response
• Support novel agent development and associated biomarker valida-
tion
• Revisit trial design approach for novel agents with consideration of 
traditionally low accrual rates in early-stage NSCLC
• Ensure adequate funding of trials and correlative studies
Screening and staging
• Integrate emerging CT scan data into screening paradigms
• Prospectively evaluate molecular screening tests
• Develop new molecular imaging and staging approaches
Conclusions: The SLC in Lung Cancer has identiﬁed several priority 
research areas to be addressed in the next 3-5 years, which will guide 
continued CCCG for advancing NSCLC research. The recommenda-
tions rely on adequate clinical trial accrual and ongoing cooperative 
group support.
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Background: Bone metastases are an important emerging problem in 
patients with lung cancer and are leading to increasing consumption of 
health care resources. 
Objectives: To assess the epidemiology, the management strategies and 
the costs of bone metastases in lung cancer; to model the management 
of these patients by a Markov model in order to evaluate the effective-
ness of different therapeutic strategies.
Methods: prospective, national, multicentric, observational, epide-
miological study planned to include 500 patients between may 2006 
and may 2007, with a one year follow up, a monthly report of skeletal-
related events and resources consumptions. The economic analysis is 
limited to the direct costs with the health care payer’s perspective.
Results: At this time, 404 patients are included by 36 centres: men: 
77,2%, median age: 61 (39-84) years, non small cell lung cancer: 90%. 
Bone diagnosis metastases is made by scintigraphy (59.7%), standard 
radiology or RMI (3.4%), and bone-scan (36.9%). At inclusion the 
median number of lesions was 4; 74.4% of patients receive an analgesic 
treatment, 41.5% a biphosphonates therapy (zoledronate in 83% of 
cases), 20.5% a radiotherapy and 5%.had a bone-surgery. 
Conclusion: complete demographic, clinical and economical datas will 
be presented at the IASCL meeting.
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Background: Little is known about the patient’s and carer’s experience 
of non small cell lung cancer (NSCLC), despite a growing research in-
terest in quality of life, psychosocial aspects and unmet needs of cancer 
patients. The aim of this project is to explore and describe the NSCLC 
patient and carer perspective in terms of their needs (including unmet 
needs) and quality of life issues. 
Method: Focus groups were conducted with 27 patients with Stage 
IIIB/IV NSCLC recruited from seven hospitals in New South Wales 
and Queensland including public and private, metropolitan and regional 
with visiting oncology services. Focus groups with 13 carers were 
conducted in three sites. A semi-structured discussion guide was used. 
Participants were asked to discuss the needs of people with NSCLC, 
impact on families, concerns about the future, interactions with health 
care providers, experiences and expectations of patient support groups. 
Discussions were audio-taped and transcribed verbatim. 
Results: Overall, participants described high satisfaction with the 
quality of health and supportive care received. However, there was a 
range of experiences relating to the degree of engagement in “driv-
ing” or “managing” their health care: some participants were satisﬁed 
with being directed through treatment, others wanted to be “one step 
ahead” of treatment delivery. One patient was particularly fearful of his 
condition and unconnected with any support service. Patient partici-
pants expressed concerns regarding the impact of NSCLC on their 
families and, in particular, their spouses. Patients described difﬁculties 
in communicating with their spouses in discussing their thoughts, fears 
and concerns about the future. Issues discussed also included need-
ing to know “how they would die”, lack of choice regarding voluntary 
euthanasia and, for younger participants, communicating and dealing 
with the reactions of their young children. Typically, carers seemed 
to “hide” their feelings about the cancer and the impact on their lives. 
They also described putting the rest of their lives “on hold” to care for 
their partners. The lack of media attention on NSCLC (or prominence 
of adverse media around smoking and lung cancer) was a concern for 
some participants and affected the extent and quality of support they 
received from family and social networks. 
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The data from these focus groups should be viewed in light that the 
patients participating were all well enough to do so. Needs of people 
with more advanced disease (and their carers) may be different. 
Conclusions: This study contributes to increased understandings of the 
patient experience, and that of informal carers, to assist in the provision 
of information for decision making and in supporting patients in coping 
with NSCLC. These ﬁndings will also contribute to understandings 
of the experiences of NSCLC patients and carers, compared to those 
with other cancers. Care should be taken in ensuring that people with 
NSCLC do not “fall through the cracks” of treatment services and are 
able to ﬁnd the support they require. 
* Margaret Adams, Tony Blackwell, Phyllis Butow, Maree Colosimo, 
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Background: Erlotinib is a potent, orally active inhibitor of EGFR 
tyrosine-kinase activity. In a randomised, phase III study (BR.21), erlo-
tinib was shown to signiﬁcantly prolong survival, delay symptom pro-
gression and improve quality of life compared with placebo in patients 
with relapsed NSCLC (Shepherd et al. NEJM 2005;353:123-32; Bezjak 
et al. JCO 2006;24:3831-7). The improvement in survival with erlotinib 
did not depend on tumour EGFR expression status. Using efﬁcacy data 
from the overall BR.21 population, combined with local health care 
utilisation data, we conducted a pharmacoeconomic analysis of erlo-
tinib in 2nd/3rd-line treatment of NSCLC in the Netherlands.
Methods: Two economic analyses were performed, one comparing er-
lotinib with docetaxel and the other with BSC. Efﬁcacy was expressed 
as life-years gained (LYG) and was calculated for erlotinib and BSC 
from the BR.21 intent-to-treat population. No head-to-head data are 
available for erlotinib and docetaxel, but clinical evidence suggests 
similar efﬁcacy (Ramalingam and Sandler, Oncologist 2006;11:655-
65). We therefore assumed LYG for docetaxel to be equal to that for 
erlotinib. LYG were extrapolated to 3 years following start of treatment 
to capture the survival data for all patients. Cost components were: 
frequency and duration of hospitalisation; outpatient consultations; 
radiotherapy; treatment of side effects; diagnostic procedures and labo-
ratory tests; drug use; and drug administration procedures. Dutch health 
care utilisation (HCU) data for patients with relapsed NSCLC were 
obtained by retrospective chart review (n=96). Twenty-four charts were 
analysed for patients treated with docetaxel, and 72 for those receiv-
ing BSC, from 4 general hospitals and 1 academic hospital. All prices 
were taken from 2004; except the erlotinib price (2005). Both cost and 
efﬁcacy results were discounted at 4%. Pharmacoeconomic analysis 
was performed with a Markov health-state model, using a base case and 
alternative scenarios. HCU data and model assumptions were approved 
by an expert panel of 10 Dutch lung cancer specialists.
Results: The average cost of treatment was €24,939 for docetaxel-
treated patients, compared with €23,436 for erlotinib-treated patients 
and €15,450 for patients on BSC. LYG were 0.84 years for docetaxel 
and erlotinib, and 0.62 years for BSC. Erlotinib was found to be cost 
saving versus docetaxel in most scenarios, except when assuming an 
unrealistically low dose of docetaxel (110mg/cycle). The incremental 
cost-effectiveness ratio (ICER) for erlotinib versus BSC was €37,551 
per LYG (CI €12,621-€72,960), based on an average treatment dura-
tion of 4.3 months. ICERs were sensitive to variations in the length and 
frequency of hospitalisation, as well as the number of outpatient con-
sultations. Assuming a willingness-to-pay (WTP) threshold of €50,000 
per LYG, and using the conﬁdence intervals of a select number of 
variables, erlotinib was found to be cost-effective compared with BSC 
in 80% of cases.
Conclusions: In patients with relapsed NSCLC, treatment with erlo-
tinib was found to be cost-saving versus docetaxel and cost-effective 
versus BSC. Based on the combined ﬁndings of clinical efﬁcacy and 
cost-effectiveness, erlotinib received unrestricted reimbursement in the 
Netherlands for patients with relapsed NSCLC.
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Background: Erythropoiesis-stimulating agents are widely used for the 
treatment of chemotherapy-induced anemia. Here we present results of 
a trial that evaluated the effect of darbepoetin alfa (DA) versus placebo 
on hemoglobin (Hb) concentration, survival, and disease progression in 
anemic cancer patients with previously untreated extensive-stage SCLC.
Methods: Patients with extensive-stage SCLC (n=597), ≥18-years old, 
and baseline Hb ≥9g/dL and ≤13g/dL, were randomly allocated 1:1 
DA:placebo. Randomization was stratiﬁed by region (Western Europe; 
Australia/North America; rest of world), performance status (0-1 versus 
2), and LDH (normal versus abnormal). DA 300µg or placebo was 
administered once per week (QW) for 4 weeks, then every 3 weeks 
(Q3W) until end of treatment. The dose was withheld if Hb increased 
≥14g/dL and resumed QW (weeks 1-4) or Q3W (week 5 to end of treat-
ment) once Hb dropped <13g/dL. Administration of study drug began 
with the ﬁrst cycle of on-study chemotherapy (cisplatin or carboplatin 
plus etoposide Q3W), continuing throughout 6 cycles. End-of-che-
motherapy period (EOCP) visits occurred up to 3 weeks after the last 
chemotherapy dose, and end-of-study treatment (EOST) visits occurred 
8 weeks after completion of chemotherapy; follow-up visits occurred 
every 3 months until death. Co-primary endpoints were mean change 
in Hb concentration during chemotherapy and survival. A prespeciﬁed 
